Company Profile
Science and Technology Saves Lives · Technology Safeguards Health
Wuhan Porida Biotechnology Co., Ltd. (hereinafter referred to as"Porida Creatures") is a pharmaceutical company dedicated to the research and development, pilot test and declaration of CAR-T immune cell drugs. It was established in September 2014 and led by Professor Zhang Tongcun, Dean of the School of Life Sciences and Health of Wuhan University of Science and Technology, A scientific and technological innovation enterprise jointly created by immunology experts, clinical medicine experts and cell biology experts from the University of Pennsylvania, Columbia University, University of Pittsburgh, University of North Carolina, University of Leeds, Peking University, Wuhan University, Academy of Military Sciences, Chinese Academy of Sciences and other universities and scientific research institutions.
Polida Biology currently has more than 6000 square meters of R & D and pilot workshops. The layout of the workshop is designed by a professional design institute according to the requirements of drug research and development and production. The workshop sites and facilities meet the requirements of GMP, and have a modern research and development-small test-pilot test-declaration process platform and quality control platform. Each workshop is fully in accordance with the requirements of GMP set up the functional operation room, and equipped with advanced and complete research and development, pilot and quality control equipment, to ensure that the pharmaceutical research of CAR-T drugs fully meet the requirements of drug declaration.
Porida Bio has formed a research and development pattern dominated by blood tumor CAR-T, with multiple research and development projects such as viral infectious disease CAR-T, solid tumor CAR-T and general CAR-T advancing in parallel. At present, the company has applied for more than 60 national patents. More than 20 patents have been authorized. Hematology tumor CAR-T has many mature targets such as CD30, CD19, CD22, CD99, CD20, BCMA, etc. for leukemia, lymphoma and multiple myeloma, and has completed more than 700 clinical trials and achieved exciting curative effects; relevant clinical data have been published in the international top blood tumor journal "Blood" and the influential medical journal "The Lancet (Lancet)"; the CD30 CAR-T cell therapy product independently developed by the company is the first domestic related product tacitly approved by the clinical trial approved by the State Drug Administration; the company has the world's first invention patent of "using CAR-T immune cells to treat HIV, it has taken the lead in carrying out human clinical research and trials in the world, which is expected to achieve the functional cure of viral HIV; the company has taken the lead in proposing the treatment strategy of CAR-T cell loaded oncolytic virus in the CAR-T treatment of solid tumors. The treatment plan is steadily advancing, and has obtained the invention patent authorization, and related clinical trials are also in the process of active development. At present, our company has been listed as a gold seed listed reserve enterprise.
"Science and technology save lives, technology guarantee health" is the purpose of Porida people to do things; we will take "innovation to lead, protect health" as our mission, unswervingly promote the process of medical development, improve human life, and be the most influential guardian of healthy China.
Has applied for national patent
Completed clinical trial studies
R & D pipeline
R & D elite
Authorized by patent
Core Team
Professor Ken Young
MD, Professor of the Department of Pathology, Duke University, Professor of the Duke Cancer Research Center, and Professor of the University of Texas MD Anderson Cancer Center.
Academician Carl H.June
Professor Carl H. June received his MD degree from Baylor College of Medicine in 1979. He is a pioneer in the field of immunotherapy and an academician of the National Academy of Sciences. He is famous all over the world for developing and studying the potential use of adoptive immunotherapy for cancer and HIV infection. He is one of the founders of CAR-T cell therapy.
Professor Zhang Tongcuun
Foreign academician of the Russian Academy of Engineering, second-class professor, doctoral supervisor. PhD, Institute of Biophysics, Chinese Academy of Sciences.
Partners
Development Process
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
2024
Company address: Floor 4 and Floor 5 (1) of Building 3, Phase 3.1, Wuhan Optics Valley International Biomedical Enterprise Accelerator, 388 Gaoxin 2nd Road, Donghu New Technology Development Zone, Wuhan City
Copyright©2012-2024 Bio-Raid All Rights Reserved Wuhan Porida Biotechnology Co., Ltd. Copyright No. 42018502002564, An Bei, E Public Network